Navigation Links
HIRC Research Alert: Health Plans Expected to Increase Adoption of Percent Copays to Manage Specialty Medications

Health Industries Research Companies (HIRC) Specialty Pharmaceuticals Service is an ongoing market research study that provides detailed analyses on health plans’ coverage and management of specialty pharmaceuticals.

(PRWEB) June 3, 2010 -- Health Industries Research Companies (HIRC) Specialty Pharmaceuticals Service is an ongoing market research study that provides detailed analyses on health plans’ coverage and management of specialty pharmaceuticals.

Adoption of percent copays for specialty medications is forecast to grow in 2011.
HIRC asked health plan executives to assess the percentage of their commercial lives covered by three types of copays — fixed, percent and no copay —for specific medications in eight specialty drug classes. While the majority of patients remain covered by fixed copays (for medications administered in the pharmacy benefit), HIRC research finds that the usage of percent copays is expected to grow to an average of 38% in 2011. This uptake is due to “growth in the price and usage of specialty medications, the overall rising cost of health care, and the poor economy,” explains Karen Lucas, Director, Specialty Pharmaceuticals Service. Ms. Lucas further comments that “the growth of percent copays, specialty tiers, and wider copay differentials will be slow and steady as many employers remain reluctant to place heavy copay burdens on their employees.”

The majority of commercial health plan members are not covered by out-of-pocket limits.
Health plan panelists were asked to indicate if their plan has out-of-pocket limits in place to cover specialty medications. The number of plans offering out-of-pocket limits in the pharmacy benefit has remained at approximately 45% of plans since 2008. Additionally, many of the plans in HIRC research that offer out-of-pocket limits also report including other pharmacy copays (e.g. oral prescription agents) within the limit. Ms. Lucas expects that “plans will continue to put out-of-pocket limits in place as plan sponsors increasingly adopt percent copays.” Notably, in spring 2010 only one-third of commercial lives represented in HIRC research are covered by out-of-pocket limits.

The Patient Copays chapter of the Specialty Pharmaceuticals Service provides insight into health plans commercial fixed and percent copay enrollment and pricing, as well as out-of-pocket limits for eight key specialty categories.

Research Methodology:
Research was conducted in January and February 2010, with 52 pharmacy and medical directors at leading health plans representing over 46 million commercial lives. Follow-up interviews were conducted with a subset of panelists. In addition to the patient copay and pricing information highlighted in this update, the following updates are included in the Specialty Pharmaceuticals Service: location of benefits coverage, formulary and utilization management trends, and physician reimbursement and specialty pharmacy provider usage.

HEALTH INDUSTRIES RESEARCH COMPANIES (HIRC) is an independent, nonpartisan organization that conducts strategic market research on trends in health care, pharmaceutical, and managed care businesses. HIRC’s benchmark studies focus on the marketing needs of pharmaceutical companies by providing research critical to the development of successful customer-focused marketing strategies.

# # #

Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. $1.8 million awarded for palliative care research to improve care of seriously ill patients
2. Basque researchers apply chemistry to restoration of paintings and dating of signatures
3. Researchers offer solutions to poisonous well-water crisis in southern Asia
4. University of Minnesota, Mayo Clinic sign research pact with Karolinska
5. American Association for Cancer Research has Record-breaking Registration at 101st Annual Meeting
6. Only 5 percent of cancer research funds are spent on metastases, yet it kills 90 percent of all cancer patients
7. Nottingham research leads to blood test for early detection of cancer
8. McGills Orphan Drug research offers hope
9. Hair Loss Research Study Reveals Important Breakthrough in the Treatment of Male Pattern Baldness
10. U of A discovery offers promising research for spinal-cord injury treatments
11. Research finds surgery outperforms drug therapy in treatment of benign prostatic hyperplasia
Post Your Comments:
(Date:12/1/2015)... Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... United States, today announced that its iconic bottle has won top honors in Beverage ... category. The Company also announced that it has been selected as a 2015 ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation ... utilization of hospital and nonhospital care, according to a recent study by the Workers ... 16th Edition , found medical payments per claim with more than seven days of ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today ... Golden Bridge Business Awards under the New Products and Services category for its ... sample management software that helps labs organize data and track samples ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... keeping their independence is everything. That is why Hollister Incorporated has launched the ... to offer this next product in the VaPro touch free catheter portfolio,” said ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 ... today announced that its Chief Executive Officer, ... the Oppenheimer Annual Healthcare Conference in New ... in the conference through a webcast on ... , --> ...
(Date:12/1/2015)... India and PITTSBURGH , ... today announced that it expects to be the first ... markets funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate ... mg) for $99 per patient, per year. Mylan partnered ... TLE400. The significantly reduced price could generate savings of ...
(Date:12/1/2015)... Breg, Inc ., a premier provider ... it has been awarded three contracts by Novation, a ... will have access to improved pricing for Breg,s portfolio ... goods dedicated to advancing orthopedic care.  ... population, rising prevalence of chronic conditions and the health ...
Breaking Medicine Technology: